Co-Diagnostics, Inc. (Nasdaq: CODX) has announced the formation of a newly organized artificial intelligence business unit, led by Chief Technology & AI Officer, Christopher Thurston, to integrate the company’s existing and planned AI applications into the Co-Dx™ Primer Ai™ platform.

Co-Dx anticipates that allocating resources to the newly formed AI business unit will enable the company to develop proprietary AI-powered diagnostics more efficiently and reduce time-to-market for new tests. The company also believes that future AI tools will be able to leverage analytics from the widespread deployment and commercialization of the Co-Dx PCR Pro to improve situational awareness during a health crisis.

This announcement follows recent news that Co-Diagnostics and Arabian Eagle Group have entered into a definitive joint venture agreement to establish CoMira Diagnostics in Saudi Arabia. CoMira is similar to CoSara Diagnostics, the company’s joint venture in India, and extends the company’s global reach.